Motilal Oswal maintains a Buy rating and sets a target price of Rs 3,145 for Ajanta Pharma due to its plans for expansion and product enhancement. The company is expected to outperform the industry with its strong MR presence and shift towards a chronic-focused portfolio. The partnership with Biocon and potential earnings growth in FY27 are also seen as significant drivers.